Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic indexRobert P. Lyon, Peter D. Senter, Svetlana O. Doronina et al.|Nature Biotechnology|2015Cited by 521
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancersLeia M. Smith, P. J. Carter, Albina Nesterova et al.|British Journal of Cancer|2008Cited by 289